XOMA Corp

Research XOMA Corp (XOMA) on Bullrun: valuation model: 17.2% undervalued, market cap USD 528.60M, P/E 26.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXOMA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal17.2% undervalued
• Market capUSD 528.60M
• P/E26.8
• Financial periodFY2025
• RevenueUSD 10.35M
• Revenue growth55.6%
• Net incomeUSD 31.71M

Valuation Snapshot

Bullrun's latest valuation model marks XOMA Corp as 17.2% undervalued; latest market cap is USD 528.60M; P/E is 26.8.

About XOMA Corp

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers;

Frequently asked questions

Is XOMA Corp overvalued or undervalued?

Bullrun's valuation model currently marks XOMA Corp as 17.2% undervalued.

What is XOMA Corp's market cap?

XOMA Corp's market capitalization is USD 528.60M.

What is XOMA Corp's P/E ratio?

XOMA Corp's price-to-earnings (P/E) ratio is 26.8.

What does XOMA Corp do?

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.